Form 4: Avadel CEO Divis Sells Shares, Options in Alkermes Acquisition

Avadel Pharmaceuticals CEO Gregory J. Divis disposed of all his ordinary shares and stock options as part of Alkermes plc's acquisition of Avadel.

Summary

• Gregory J. Divis, Chief Executive Officer and Director of Avadel Pharmaceuticals plc, reported the disposition of all his beneficial ownership in Avadel's ordinary shares and stock options.
• The transactions occurred on February 12, 2026, as a result of Alkermes plc's acquisition of Avadel Pharmaceuticals plc through a scheme of arrangement under Irish law.
• Each outstanding ordinary share was converted into $21.00 in cash and one non-transferable contingent value right (CVR) for a potential additional $1.50 per share, contingent upon achievement of certain milestones.
• Restricted Stock Awards vested fully at the Effective Time and were treated in the same manner as ordinary shares.
• Stock options were canceled and exchanged for cash (equal to the product of the number of shares subject to the option multiplied by the excess of the $21.00 cash consideration over the option's exercise price) and one CVR per underlying share.
• Divis disposed of 211,105 direct ordinary shares and 10,000 indirect ordinary shares held by the Gregory J. Divis Jr. Revocable Trust.
• He also disposed of stock options covering a total of 2,560,000 ordinary shares with various exercise prices ranging from $1.71 to $13.57.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Avadel shareholders, as the acquisition provides immediate liquidity and a potential future payment, reflecting a successful strategic exit for the company.

Positives

• The acquisition by Alkermes plc provided a clear exit strategy and liquidity for Avadel shareholders.
• Shareholders received a fixed cash consideration of $21.00 per share, providing certainty of value.
• The inclusion of a Contingent Value Right (CVR) offers potential upside of an additional $1.50 per share upon achievement of certain milestones.
• Restricted Stock Awards vested in full at the effective time of the acquisition, benefiting employees holding these awards.

Negatives

• The disposition of all shares and options by the CEO indicates the cessation of Avadel Pharmaceuticals as an independent entity, removing its stock from public trading.
• The CVR component introduces uncertainty regarding the full potential value of $1.50 per share, as it is contingent on future milestones.

Risks

• The Contingent Value Right (CVR) payment of $1.50 per share is contingent upon the achievement of certain milestones, meaning its realization is not guaranteed.

Future Outlook

The filing primarily reports a past transaction, the acquisition of Avadel by Alkermes, and the resulting disposition of securities by an insider. The future outlook for Avadel as an independent entity is nil, as it has been acquired. The only forward-looking aspect is the potential for the CVR payment, which depends on future milestone achievement by the acquiring entity.

Industry Context

StockSavvy.ai notes that acquisitions like this are common in the pharmaceutical industry, often driven by strategic portfolio expansion, access to new drug pipelines, or market consolidation. The use of Contingent Value Rights (CVRs) is a frequent mechanism in biotech and pharma mergers and acquisitions to bridge valuation gaps and incentivize post-acquisition performance related to specific drug development or regulatory milestones.

Comparison to Industry Standards

• The acquisition price of $21.00 per share, plus a potential $1.50 CVR, should be compared to Avadel's historical trading prices and analyst price targets prior to the acquisition announcement to assess the premium offered to shareholders.
• The structure of the deal, including a fixed cash component and a contingent value right, is a common M&A strategy in the pharmaceutical sector, similar to deals such as Bristol Myers Squibb's acquisition of Celgene, which also included CVRs tied to regulatory approvals.
• The exercise prices of the disposed stock options, ranging from $1.71 to $13.57, indicate that many of these options were significantly in-the-money relative to the $21.00 cash consideration, suggesting substantial gains for the option holder.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $21.00 cash per share and a CVR for a potential additional $1.50, providing liquidity and potential upside.
• Employees (holding Restricted Stock Awards/Options): Benefited from full vesting of awards and cash/CVR exchange, providing a payout for their equity.
• Company (Avadel): Ceased to exist as an independent publicly traded entity, becoming part of Alkermes plc.

Next Steps

• Monitoring the achievement of milestones for the Contingent Value Rights (CVRs) to determine if the additional $1.50 per share payment will be realized.

Key Dates

Keywords

AVADEL PHARMACEUTICALS PLC, AVDL, Alkermes plc, acquisition, merger, Form 4, insider transaction, stock options, contingent value right, CVR, scheme of arrangement, Gregory J. Divis